Skip to main navigation Skip to search Skip to main content

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

  • Ki Hyeong Lee
  • , Byoung Chul Cho
  • , Myung Ju Ahn
  • , Yun Gyoo Lee
  • , Youngjoo Lee
  • , Jong Seok Lee
  • , Joo Hang Kim
  • , Young Joo Min
  • , Gyeong Won Lee
  • , Sung Sook Lee
  • , Kyung Hee Lee
  • , Yoon Ho Ko
  • , Byoung Yong Shim
  • , Sang We Kim
  • , Sang Won Shin
  • , Jin Hyuk Choi
  • , Dong Wan Kim
  • , Eun Kyung Cho
  • , Keon Uk Park
  • , Jin Soo Kim
  • Sang Hoon Chun, Jangyoung Wang, Seok Young Choi, Jin Hyoung Kang

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science